Amneal Pharmaceuticals (AMRX) Total Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $728.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 32.33% year-over-year to $728.0 million; the TTM figure through Mar 2026 stood at $728.0 million (down 32.33% YoY), while the FY2025 annual figure was $881.6 million, down 21.96% from the prior year.
• Total Current Liabilities was $728.0 million for Q1 2026 at Amneal Pharmaceuticals, down from $881.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.1 billion in Q4 2024 to a low of $602.0 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $887.2 million across 5 years, with a median of $846.6 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities jumped 47.59% in 2022, then sank 32.33% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $752.8 million in 2022, then climbed by 12.46% to $846.6 million in 2023, then jumped by 33.45% to $1.1 billion in 2024, then decreased by 21.96% to $881.6 million in 2025, then declined by 17.42% to $728.0 million in 2026.
• The last three Total Current Liabilities figures came in at $728.0 million (Q1 2026), $881.6 million (Q4 2025), and $862.1 million (Q3 2025), per Business Quant data.